Olema Pharmaceuticals
OLMA
7.94
+0.02
+0.25%
Olema Pharmaceuticals
US · OLMA
#3521 by market cap
Listed 2020
7.94
+0.02
+0.25%
Live - 5344 symbols - heartbeat 268s ago
· 2026-10-08 07:38
Pre-market
8.10
+2.02%
After-hours
7.84
-1.32%
- Market cap
- 694.73M
- P/E (TTM)i
- -3.75
- P/Bi
- 1.61
- EPSi
- -1.87
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on OLMA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Key ratios & quality
- Enterprise valuei
- 193.42M
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 386.00K | 403.00K | 7.82M | 20.39M | 24.71M | 18.82M | 17.74M | 21.00M |
| Research & development | 1.69M | 3.92M | 13.70M | 51.10M | 82.27M | 86.14M | 124.52M | 157.70M |
| Operating profit | -2.08M | -4.32M | -21.53M | -71.49M | -106.99M | -104.96M | -142.26M | -178.70M |
| Pretax profit | -2.20M | -4.32M | -22.12M | -71.10M | -104.79M | -96.66M | -129.47M | -162.45M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -2.20M | -4.32M | -22.12M | -71.10M | -104.79M | -96.66M | -129.47M | -162.45M |
| Basic EPS | 0 | 0 | -3 | -2 | -3 | -2 | -2 | -2 |
| Diluted EPS | -0.16 | -0.31 | -3.42 | -1.80 | -2.62 | -2.14 | -2.20 | -1.87 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.25M | 3.96M | 5.93M | 6.86M | 8.75M | 9.39M |
| Research & development | 30.62M | 43.90M | 39.95M | 43.22M | 49.23M | 57.79M |
| Operating profit | -34.87M | -47.86M | -45.88M | -50.08M | -57.99M | -67.18M |
| Pretax profit | -30.39M | -43.78M | -42.22M | -46.06M | -53.09M | -63.20M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -30.39M | -43.78M | -42.22M | -46.06M | -53.09M | -63.20M |
| Basic EPS | 0 | -1 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.36 | -0.51 | -0.49 | -0.51 | -0.52 | -0.61 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.24M | 103.00K | 342.14M | 290.69M | 208.90M | 266.51M | 438.47M | 515.45M |
| Cash & ST investments | 3.15M | 68.00K | 338.55M | 287.25M | 204.42M | 261.81M | 434.09M | 505.44M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 3.27M | 132.00K | 342.72M | 295.95M | 215.65M | 276.95M | 450.98M | 533.43M |
| Total current liabilities | 201.00K | 1.38M | 4.59M | 9.02M | 16.55M | 21.62M | 41.76M | 51.80M |
| Short-term debt | -- | -- | -- | 931.00K | 1.02M | 988.00K | 1.17M | 1.12M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | 3.00M |
| Total liabilities | 9,549,000.00 | 10,726,000.00 | 4,585,000.00 | 11,377,000.00 | 18,099,000.00 | 23,050,000.00 | 42,015,000.00 | 54,871,000.00 |
| Total equity | -6.28M | -10.59M | 338.14M | 284.57M | 197.55M | 253.90M | 408.96M | 478.56M |
| Retained earnings | -6.45M | -10.76M | -33.09M | -104.19M | -208.98M | -305.63M | -435.11M | -597.56M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 396.66M | 367.73M | 334.33M | 515.45M | 513.23M | 469.88M |
| Cash & ST investments | 392.71M | 361.91M | 328.96M | 505.44M | 505.35M | 461.07M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 409.64M | 382.00M | 352.45M | 533.43M | 530.65M | 486.58M |
| Total current liabilities | 26.06M | 33.16M | 41.66M | 51.80M | 47.17M | 53.01M |
| Short-term debt | 1.03M | 1.15M | 1.17M | 1.12M | 956.00K | 660.00K |
| Long-term debt | -- | 3.00M | 3.00M | 3.00M | 3.00M | 3.00M |
| Total liabilities | 26,187,000.00 | 36,766,000.00 | 44,965,000.00 | 54,871,000.00 | 50,167,000.00 | 56,014,000.00 |
| Total equity | 383.45M | 345.24M | 307.49M | 478.56M | 480.48M | 430.56M |
| Retained earnings | -465.50M | -509.28M | -551.50M | -597.56M | -650.65M | -713.85M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -2.18M | -3.08M | -19.87M | -50.69M | -82.07M | -83.73M | -104.35M | -146.72M |
| Depreciation & amortization | 8.00K | 9.00K | 11.00K | 163.00K | 357.00K | 377.00K | 393.00K | 490.00K |
| Free cash flow | -2.18M | -3.08M | -19.92M | -52.27M | -82.43M | -83.73M | -104.51M | -146.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 220.55M | -- | 0 | 129.74M | 266.29M | 205.39M |
| Ending cash balance | 3.15M | 68.00K | 338.55M | 13.81M | 23.70M | 68.54M | 139.48M | 48.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -43.98M | -29.88M | -34.53M | -38.33M | -45.99M | -45.90M |
| Depreciation & amortization | 128.00K | 132.00K | 43.00K | 187.00K | 119.00K | 102.00K |
| Free cash flow | -43.98M | -29.88M | -34.53M | -38.33M | -45.99M | -46.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 205.39M | 41.92M | 0 |
| Ending cash balance | 50.64M | 52.47M | 35.26M | 48.30M | 52.55M | 48.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -14.65 | -22.83 | -43.47 | -42.82 | -39.07 | -36.61 |
| ROA %i | -67.17 | -253.66 | -13.99 | -22.26 | -40.97 | -39.24 | -35.57 | -33.00 |
| ROIC %i | -- | -- | -14.29 | -22.74 | -43.86 | -46.00 | -42.64 | -40.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -32.57 | -36.96 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 16.13 | 0.07 | 74.62 | 32.23 | 12.62 | 12.33 | 10.50 | 9.95 |
| Quick ratioi | 15.67 | 0.05 | 73.84 | 31.86 | 12.37 | 12.14 | 10.45 | 9.84 |
| Debt / assetsi | -- | -- | 0.00 | 1.11 | 1.19 | 0.87 | 0.32 | 0.79 |
| LT debt / equityi | -- | -- | -- | 0.83 | 0.78 | 0.56 | 0.06 | 0.64 |
| Interest coveragei | -77.46 | -- | -32.88 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -41.59 | -49.72 | -59.22 | -36.61 | -42.86 | -52.74 |
| ROA %i | -38.29 | -44.71 | -51.48 | -33.00 | -39.38 | -47.10 |
| ROIC %i | -45.82 | -54.25 | -64.56 | -40.01 | -46.40 | -56.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.22 | 11.09 | 8.03 | 9.95 | 10.88 | 8.86 |
| Quick ratioi | 15.14 | 11.00 | 7.97 | 9.84 | 10.79 | 8.76 |
| Debt / assetsi | 0.28 | 1.24 | 1.27 | 0.79 | 0.75 | 0.75 |
| LT debt / equityi | 0.03 | 1.04 | 1.08 | 0.64 | 0.62 | 0.70 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:38:44 · For reference only, not investment advice and not tailored to your situation.